Instaryl LS Oral Drops is a combination medication containing Levosalbutamol (0.25 mg/ml), Ambroxol (7.5 mg/ml), and Guaifenesin (12.5 mg/ml), formulated to provide symptomatic relief in respiratory conditions characterized by bronchospasm, excessive mucus production, and cough. Levosalbutamol, a selective β2-adrenergic receptor agonist, acts as a bronchodilator by relaxing the smooth muscles of the airways, thereby improving airflow and alleviating bronchospasm. Ambroxol serves as a mucolytic agent, facilitating the breakdown and clearance of viscous mucus from the respiratory tract, which enhances mucociliary transport and eases expectoration. Guaifenesin, an expectorant, promotes the hydration of respiratory tract secretions, reducing mucus viscosity and facilitating productive cough. The combined pharmacological actions of these agents make Instaryl LS Oral Drops effective in managing conditions such as acute and chronic bronchitis, asthma exacerbations, and other obstructive airway diseases where bronchoconstriction and mucus retention are prominent. The oral drop formulation allows for precise dosing and ease of administration, particularly in pediatric and geriatric populations. Use of Instaryl LS should be guided by a healthcare professional, considering contraindications and potential drug interactions. Adverse effects may include tremors, gastrointestinal disturbances, and hypersensitivity reactions; patients should be monitored accordingly.